Loading…
Degradation of a connexin40 mutant linked to atrial fibrillation is accelerated
Abstract Several Cx40 mutants have been identified in patients with atrial fibrillation (AF). We have been working to identify physiological or cell biological abnormalities of several of these human mutants that might explain how they contribute to disease pathogenesis. Wild type (wt) Cx40 or four...
Saved in:
Published in: | Journal of molecular and cellular cardiology 2014-09, Vol.74, p.330-339 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c514t-d8c84385f827eff765f78ac2f2876f7fa956cb99c73707bc6edc6a4f54ea05833 |
---|---|
cites | cdi_FETCH-LOGICAL-c514t-d8c84385f827eff765f78ac2f2876f7fa956cb99c73707bc6edc6a4f54ea05833 |
container_end_page | 339 |
container_issue | |
container_start_page | 330 |
container_title | Journal of molecular and cellular cardiology |
container_volume | 74 |
creator | Gemel, Joanna Simon, Adria R Patel, Dakshesh Xu, Qin Matiukas, Arvydas Veenstra, Richard D Beyer, Eric C |
description | Abstract Several Cx40 mutants have been identified in patients with atrial fibrillation (AF). We have been working to identify physiological or cell biological abnormalities of several of these human mutants that might explain how they contribute to disease pathogenesis. Wild type (wt) Cx40 or four different mutants (P88S, G38D, V85I, and L229M) were expressed by the transfection of communication-deficient HeLa cells or HL-1 cardiomyocytes. Biophysical channel properties and the sub-cellular localization and protein levels of Cx40 were characterized. Wild type Cx40 and all mutants except P88S formed gap junction plaques and induced significant gap junctional conductances. The functional mutants showed only modest alterations of single channel conductances or gating by trans-junctional voltage as compared to wtCx40. However, immunoblotting indicated that the steady state levels of G38D, V85I, and L229M were reduced relative to wtCx40; most strikingly, G38D was only 20–31% of wild type levels. After the inhibition of protein synthesis with cycloheximide, G38D (and to a lesser extent the other mutants) disappeared much faster than wtCx40. Treatment with the proteasomal inhibitor, epoxomicin, greatly increased levels of G38D and restored the abundance of gap junctions and the extent of intercellular dye transfer. Thus, G38D, V85I, and L229M are functional mutants of Cx40 with small alterations of physiological properties, but accelerated degradation by the proteasome. These findings suggest a novel mechanism (protein instability) for the pathogenesis of AF due to a connexin mutation and a novel approach to therapy (protease inhibition). |
doi_str_mv | 10.1016/j.yjmcc.2014.06.010 |
format | article |
fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4135452</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022282814002041</els_id><sourcerecordid>S0022282814002041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c514t-d8c84385f827eff765f78ac2f2876f7fa956cb99c73707bc6edc6a4f54ea05833</originalsourceid><addsrcrecordid>eNqFkcFuFDEMhiNERZfCEyCheYGZOplkkjlQCRUoSJV6aDlHWY9TMp3NVJls1X17smypgAsHy5bs_7f8mbF3HBoOvDsdm924QWwEcNlA1wCHF2zFoVe1UUa-ZCsAIWphhDlmr5dlBIBetu0rdixkr9sSK3b1iW6TG1wOc6xmX7kK5xjpMUQJ1WabXczVFOIdDVWeK5dTcFPlwzqFaTqIwlI5RJoouUzDG3bk3bTQ26d8wr5_-Xxz_rW-vLr4dv7xskbFZa4Hg0a2RnkjNHmvO-W1cSi8MLrz2rtedbjue9StBr3GjgbsnPRKkgNl2vaEnR1877frTWlSzMlN9j6FjUs7O7tg_-7E8MPezg9W8lZJJYpBezDANC9LIv-s5WD3fO1of_G1e74WOlv4FtX7P9c-a34DLQMfDgNUjn8IlOyCgSLSEBJhtsMc_rPg7B89FvwB3XRHO1rGeZti4Wq5XYQFe71_8f7DXJYKynE_AaQOo-I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Degradation of a connexin40 mutant linked to atrial fibrillation is accelerated</title><source>ScienceDirect Journals</source><creator>Gemel, Joanna ; Simon, Adria R ; Patel, Dakshesh ; Xu, Qin ; Matiukas, Arvydas ; Veenstra, Richard D ; Beyer, Eric C</creator><creatorcontrib>Gemel, Joanna ; Simon, Adria R ; Patel, Dakshesh ; Xu, Qin ; Matiukas, Arvydas ; Veenstra, Richard D ; Beyer, Eric C</creatorcontrib><description>Abstract Several Cx40 mutants have been identified in patients with atrial fibrillation (AF). We have been working to identify physiological or cell biological abnormalities of several of these human mutants that might explain how they contribute to disease pathogenesis. Wild type (wt) Cx40 or four different mutants (P88S, G38D, V85I, and L229M) were expressed by the transfection of communication-deficient HeLa cells or HL-1 cardiomyocytes. Biophysical channel properties and the sub-cellular localization and protein levels of Cx40 were characterized. Wild type Cx40 and all mutants except P88S formed gap junction plaques and induced significant gap junctional conductances. The functional mutants showed only modest alterations of single channel conductances or gating by trans-junctional voltage as compared to wtCx40. However, immunoblotting indicated that the steady state levels of G38D, V85I, and L229M were reduced relative to wtCx40; most strikingly, G38D was only 20–31% of wild type levels. After the inhibition of protein synthesis with cycloheximide, G38D (and to a lesser extent the other mutants) disappeared much faster than wtCx40. Treatment with the proteasomal inhibitor, epoxomicin, greatly increased levels of G38D and restored the abundance of gap junctions and the extent of intercellular dye transfer. Thus, G38D, V85I, and L229M are functional mutants of Cx40 with small alterations of physiological properties, but accelerated degradation by the proteasome. These findings suggest a novel mechanism (protein instability) for the pathogenesis of AF due to a connexin mutation and a novel approach to therapy (protease inhibition).</description><identifier>ISSN: 0022-2828</identifier><identifier>EISSN: 1095-8584</identifier><identifier>DOI: 10.1016/j.yjmcc.2014.06.010</identifier><identifier>PMID: 24973497</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Action Potentials - drug effects ; Animals ; Atrial fibrillation ; Atrial Fibrillation - genetics ; Atrial Fibrillation - metabolism ; Atrial Fibrillation - pathology ; Cardiovascular ; Cell Line, Tumor ; Connexin40 ; Connexins - genetics ; Connexins - metabolism ; Cycloheximide - pharmacology ; Gap Junction alpha-5 Protein ; Gap junctions ; Gap Junctions - drug effects ; Gap Junctions - metabolism ; Gene Expression Regulation ; Heart Atria - drug effects ; Heart Atria - metabolism ; Heart Atria - pathology ; Humans ; Ion channels ; Mice ; Mutation ; Myocytes, Cardiac - drug effects ; Myocytes, Cardiac - metabolism ; Myocytes, Cardiac - pathology ; Oligopeptides - pharmacology ; Patch-Clamp Techniques ; Proteasome ; Proteasome Endopeptidase Complex - drug effects ; Proteasome Endopeptidase Complex - metabolism ; Proteasome Inhibitors - pharmacology ; Protein degradation ; Protein Stability ; Protein Synthesis Inhibitors - pharmacology ; Proteolysis ; Signal Transduction ; Transgenes ; Ubiquitination</subject><ispartof>Journal of molecular and cellular cardiology, 2014-09, Vol.74, p.330-339</ispartof><rights>Elsevier Ltd</rights><rights>2014 Elsevier Ltd</rights><rights>Copyright © 2014 Elsevier Ltd. All rights reserved.</rights><rights>2014 Elsevier Ltd. All rights reserved. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c514t-d8c84385f827eff765f78ac2f2876f7fa956cb99c73707bc6edc6a4f54ea05833</citedby><cites>FETCH-LOGICAL-c514t-d8c84385f827eff765f78ac2f2876f7fa956cb99c73707bc6edc6a4f54ea05833</cites><orcidid>0000-0001-8044-1356</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24973497$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gemel, Joanna</creatorcontrib><creatorcontrib>Simon, Adria R</creatorcontrib><creatorcontrib>Patel, Dakshesh</creatorcontrib><creatorcontrib>Xu, Qin</creatorcontrib><creatorcontrib>Matiukas, Arvydas</creatorcontrib><creatorcontrib>Veenstra, Richard D</creatorcontrib><creatorcontrib>Beyer, Eric C</creatorcontrib><title>Degradation of a connexin40 mutant linked to atrial fibrillation is accelerated</title><title>Journal of molecular and cellular cardiology</title><addtitle>J Mol Cell Cardiol</addtitle><description>Abstract Several Cx40 mutants have been identified in patients with atrial fibrillation (AF). We have been working to identify physiological or cell biological abnormalities of several of these human mutants that might explain how they contribute to disease pathogenesis. Wild type (wt) Cx40 or four different mutants (P88S, G38D, V85I, and L229M) were expressed by the transfection of communication-deficient HeLa cells or HL-1 cardiomyocytes. Biophysical channel properties and the sub-cellular localization and protein levels of Cx40 were characterized. Wild type Cx40 and all mutants except P88S formed gap junction plaques and induced significant gap junctional conductances. The functional mutants showed only modest alterations of single channel conductances or gating by trans-junctional voltage as compared to wtCx40. However, immunoblotting indicated that the steady state levels of G38D, V85I, and L229M were reduced relative to wtCx40; most strikingly, G38D was only 20–31% of wild type levels. After the inhibition of protein synthesis with cycloheximide, G38D (and to a lesser extent the other mutants) disappeared much faster than wtCx40. Treatment with the proteasomal inhibitor, epoxomicin, greatly increased levels of G38D and restored the abundance of gap junctions and the extent of intercellular dye transfer. Thus, G38D, V85I, and L229M are functional mutants of Cx40 with small alterations of physiological properties, but accelerated degradation by the proteasome. These findings suggest a novel mechanism (protein instability) for the pathogenesis of AF due to a connexin mutation and a novel approach to therapy (protease inhibition).</description><subject>Action Potentials - drug effects</subject><subject>Animals</subject><subject>Atrial fibrillation</subject><subject>Atrial Fibrillation - genetics</subject><subject>Atrial Fibrillation - metabolism</subject><subject>Atrial Fibrillation - pathology</subject><subject>Cardiovascular</subject><subject>Cell Line, Tumor</subject><subject>Connexin40</subject><subject>Connexins - genetics</subject><subject>Connexins - metabolism</subject><subject>Cycloheximide - pharmacology</subject><subject>Gap Junction alpha-5 Protein</subject><subject>Gap junctions</subject><subject>Gap Junctions - drug effects</subject><subject>Gap Junctions - metabolism</subject><subject>Gene Expression Regulation</subject><subject>Heart Atria - drug effects</subject><subject>Heart Atria - metabolism</subject><subject>Heart Atria - pathology</subject><subject>Humans</subject><subject>Ion channels</subject><subject>Mice</subject><subject>Mutation</subject><subject>Myocytes, Cardiac - drug effects</subject><subject>Myocytes, Cardiac - metabolism</subject><subject>Myocytes, Cardiac - pathology</subject><subject>Oligopeptides - pharmacology</subject><subject>Patch-Clamp Techniques</subject><subject>Proteasome</subject><subject>Proteasome Endopeptidase Complex - drug effects</subject><subject>Proteasome Endopeptidase Complex - metabolism</subject><subject>Proteasome Inhibitors - pharmacology</subject><subject>Protein degradation</subject><subject>Protein Stability</subject><subject>Protein Synthesis Inhibitors - pharmacology</subject><subject>Proteolysis</subject><subject>Signal Transduction</subject><subject>Transgenes</subject><subject>Ubiquitination</subject><issn>0022-2828</issn><issn>1095-8584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqFkcFuFDEMhiNERZfCEyCheYGZOplkkjlQCRUoSJV6aDlHWY9TMp3NVJls1X17smypgAsHy5bs_7f8mbF3HBoOvDsdm924QWwEcNlA1wCHF2zFoVe1UUa-ZCsAIWphhDlmr5dlBIBetu0rdixkr9sSK3b1iW6TG1wOc6xmX7kK5xjpMUQJ1WabXczVFOIdDVWeK5dTcFPlwzqFaTqIwlI5RJoouUzDG3bk3bTQ26d8wr5_-Xxz_rW-vLr4dv7xskbFZa4Hg0a2RnkjNHmvO-W1cSi8MLrz2rtedbjue9StBr3GjgbsnPRKkgNl2vaEnR1877frTWlSzMlN9j6FjUs7O7tg_-7E8MPezg9W8lZJJYpBezDANC9LIv-s5WD3fO1of_G1e74WOlv4FtX7P9c-a34DLQMfDgNUjn8IlOyCgSLSEBJhtsMc_rPg7B89FvwB3XRHO1rGeZti4Wq5XYQFe71_8f7DXJYKynE_AaQOo-I</recordid><startdate>20140901</startdate><enddate>20140901</enddate><creator>Gemel, Joanna</creator><creator>Simon, Adria R</creator><creator>Patel, Dakshesh</creator><creator>Xu, Qin</creator><creator>Matiukas, Arvydas</creator><creator>Veenstra, Richard D</creator><creator>Beyer, Eric C</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8044-1356</orcidid></search><sort><creationdate>20140901</creationdate><title>Degradation of a connexin40 mutant linked to atrial fibrillation is accelerated</title><author>Gemel, Joanna ; Simon, Adria R ; Patel, Dakshesh ; Xu, Qin ; Matiukas, Arvydas ; Veenstra, Richard D ; Beyer, Eric C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c514t-d8c84385f827eff765f78ac2f2876f7fa956cb99c73707bc6edc6a4f54ea05833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Action Potentials - drug effects</topic><topic>Animals</topic><topic>Atrial fibrillation</topic><topic>Atrial Fibrillation - genetics</topic><topic>Atrial Fibrillation - metabolism</topic><topic>Atrial Fibrillation - pathology</topic><topic>Cardiovascular</topic><topic>Cell Line, Tumor</topic><topic>Connexin40</topic><topic>Connexins - genetics</topic><topic>Connexins - metabolism</topic><topic>Cycloheximide - pharmacology</topic><topic>Gap Junction alpha-5 Protein</topic><topic>Gap junctions</topic><topic>Gap Junctions - drug effects</topic><topic>Gap Junctions - metabolism</topic><topic>Gene Expression Regulation</topic><topic>Heart Atria - drug effects</topic><topic>Heart Atria - metabolism</topic><topic>Heart Atria - pathology</topic><topic>Humans</topic><topic>Ion channels</topic><topic>Mice</topic><topic>Mutation</topic><topic>Myocytes, Cardiac - drug effects</topic><topic>Myocytes, Cardiac - metabolism</topic><topic>Myocytes, Cardiac - pathology</topic><topic>Oligopeptides - pharmacology</topic><topic>Patch-Clamp Techniques</topic><topic>Proteasome</topic><topic>Proteasome Endopeptidase Complex - drug effects</topic><topic>Proteasome Endopeptidase Complex - metabolism</topic><topic>Proteasome Inhibitors - pharmacology</topic><topic>Protein degradation</topic><topic>Protein Stability</topic><topic>Protein Synthesis Inhibitors - pharmacology</topic><topic>Proteolysis</topic><topic>Signal Transduction</topic><topic>Transgenes</topic><topic>Ubiquitination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gemel, Joanna</creatorcontrib><creatorcontrib>Simon, Adria R</creatorcontrib><creatorcontrib>Patel, Dakshesh</creatorcontrib><creatorcontrib>Xu, Qin</creatorcontrib><creatorcontrib>Matiukas, Arvydas</creatorcontrib><creatorcontrib>Veenstra, Richard D</creatorcontrib><creatorcontrib>Beyer, Eric C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of molecular and cellular cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gemel, Joanna</au><au>Simon, Adria R</au><au>Patel, Dakshesh</au><au>Xu, Qin</au><au>Matiukas, Arvydas</au><au>Veenstra, Richard D</au><au>Beyer, Eric C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Degradation of a connexin40 mutant linked to atrial fibrillation is accelerated</atitle><jtitle>Journal of molecular and cellular cardiology</jtitle><addtitle>J Mol Cell Cardiol</addtitle><date>2014-09-01</date><risdate>2014</risdate><volume>74</volume><spage>330</spage><epage>339</epage><pages>330-339</pages><issn>0022-2828</issn><eissn>1095-8584</eissn><abstract>Abstract Several Cx40 mutants have been identified in patients with atrial fibrillation (AF). We have been working to identify physiological or cell biological abnormalities of several of these human mutants that might explain how they contribute to disease pathogenesis. Wild type (wt) Cx40 or four different mutants (P88S, G38D, V85I, and L229M) were expressed by the transfection of communication-deficient HeLa cells or HL-1 cardiomyocytes. Biophysical channel properties and the sub-cellular localization and protein levels of Cx40 were characterized. Wild type Cx40 and all mutants except P88S formed gap junction plaques and induced significant gap junctional conductances. The functional mutants showed only modest alterations of single channel conductances or gating by trans-junctional voltage as compared to wtCx40. However, immunoblotting indicated that the steady state levels of G38D, V85I, and L229M were reduced relative to wtCx40; most strikingly, G38D was only 20–31% of wild type levels. After the inhibition of protein synthesis with cycloheximide, G38D (and to a lesser extent the other mutants) disappeared much faster than wtCx40. Treatment with the proteasomal inhibitor, epoxomicin, greatly increased levels of G38D and restored the abundance of gap junctions and the extent of intercellular dye transfer. Thus, G38D, V85I, and L229M are functional mutants of Cx40 with small alterations of physiological properties, but accelerated degradation by the proteasome. These findings suggest a novel mechanism (protein instability) for the pathogenesis of AF due to a connexin mutation and a novel approach to therapy (protease inhibition).</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>24973497</pmid><doi>10.1016/j.yjmcc.2014.06.010</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-8044-1356</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2828 |
ispartof | Journal of molecular and cellular cardiology, 2014-09, Vol.74, p.330-339 |
issn | 0022-2828 1095-8584 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4135452 |
source | ScienceDirect Journals |
subjects | Action Potentials - drug effects Animals Atrial fibrillation Atrial Fibrillation - genetics Atrial Fibrillation - metabolism Atrial Fibrillation - pathology Cardiovascular Cell Line, Tumor Connexin40 Connexins - genetics Connexins - metabolism Cycloheximide - pharmacology Gap Junction alpha-5 Protein Gap junctions Gap Junctions - drug effects Gap Junctions - metabolism Gene Expression Regulation Heart Atria - drug effects Heart Atria - metabolism Heart Atria - pathology Humans Ion channels Mice Mutation Myocytes, Cardiac - drug effects Myocytes, Cardiac - metabolism Myocytes, Cardiac - pathology Oligopeptides - pharmacology Patch-Clamp Techniques Proteasome Proteasome Endopeptidase Complex - drug effects Proteasome Endopeptidase Complex - metabolism Proteasome Inhibitors - pharmacology Protein degradation Protein Stability Protein Synthesis Inhibitors - pharmacology Proteolysis Signal Transduction Transgenes Ubiquitination |
title | Degradation of a connexin40 mutant linked to atrial fibrillation is accelerated |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T09%3A28%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Degradation%20of%20a%20connexin40%20mutant%20linked%20to%20atrial%20fibrillation%20is%20accelerated&rft.jtitle=Journal%20of%20molecular%20and%20cellular%20cardiology&rft.au=Gemel,%20Joanna&rft.date=2014-09-01&rft.volume=74&rft.spage=330&rft.epage=339&rft.pages=330-339&rft.issn=0022-2828&rft.eissn=1095-8584&rft_id=info:doi/10.1016/j.yjmcc.2014.06.010&rft_dat=%3Celsevier_pubme%3ES0022282814002041%3C/elsevier_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c514t-d8c84385f827eff765f78ac2f2876f7fa956cb99c73707bc6edc6a4f54ea05833%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/24973497&rfr_iscdi=true |